DIABETIC MACULAR OEDEMA

A randomised study involving 111 eyes of 105 patients with diabetic macular oedema showed that, compared with baseline values, visual acuity improved significantly more at three and six months among patients receiving triamcinolone alone or in combination with bevacizumab than in eyes receiving bevacizumab alone. All three treatments produce significant reductions in central macular thickness throughout follow-up, with greater reductions during the first months of therapy in the triamcinolone groups. However, by 12 months the groups had statistically similar results in terms of both macular thickness and visual acuity
(Lim et al, Ophthalmologica 2012; 227: 00-106).
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.